StockWatch
·

Medplus Health Services Ltd Q2 FY27 Results

MEDPLUSQ2 FY27 Results
Filing
Result:Steady· Market: Flat#Margin squeeze#Base effect

Beat/Miss: Inline

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue2.0K8.4%21.3%
Total Income2.1K8.3%21.3%
Expenditure2.0K7.0%22.1%
PBT70.1567.5%1.8%
Net Profit56.0769.0%1.0%
OPM8.35%1.26pp0.51pp
NPM2.72%0.97pp0.55pp
EPS4.7371.4%2.2%
View full financials

Revenue grew a strong 21.3% YoY but adjusted PAT grew only 1% as rising finance costs and depreciation from store expansion absorbed nearly all operating gains, leaving net margin compression — in-line/ordinary for the sector rather than a standout.

Q2 FY-2027 RESULTS · MEDPLUS

MedPlus Q2 FY27: revenue up 21% YoY, but consolidated PAT nearly flat as lease costs bite margin

PAT +1.02% YoY · revenue +21.3% · margins compressing

27 Oct 2026 · 3 min read
Revenue

₹2,037.11 Cr

+21.3% YoY

PAT (consolidated)

₹56.07 Cr

+1.02% YoY

Net margin

2.72%

-0.5pp YoY

EPS

₹4.73

MedPlus' consolidated (primary basis) Q2 FY27 revenue rose 21.3% YoY to ₹2,037.1 Cr (₹1,679.3 Cr a year ago) and 8.4% QoQ (₹1,879.6 Cr), but consolidated PAT grew just 1.0% YoY to ₹56.1 Cr (₹55.5 Cr), and basic EPS inched up to ₹4.73 from ₹4.63. On a YoY basis — the primary lens — this is a clear case of profit growth trailing revenue growth: net profit margin (on total income) compressed to 2.73% from 3.27% a year ago. QoQ the numbers look dramatic (PAT +69%, NPM 1.75%→2.73%), but Q2 (Jul-Sep) is a seasonally firmer quarter for pharmacy retail, so that sequential jump is a seasonality artifact rather than a trend reversal and should not headline over the weak YoY print.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹2,037.11 Cr+8.4%+21.3%
Expenses₹1,987.5 Cr+7%+22.1%
PAT₹56.07 Cr+69.04%+1.02%
Net margin2.72%+1pp-0.5pp
EPS₹4.73+71.4%+2.2%

The margin bridge: gross margin (revenue less cost of materials, purchases and inventory movement) was 25.1%, up ~58 bps QoQ from 24.5% — in line with, and slightly ahead of, management's guided private-label-led recovery of +0.3-0.5pp per quarter from the last concall. But gross margin is still down ~108 bps YoY from 26.2%, so the recovery is incremental, not complete. The real drag sits below the gross-margin line: consolidated finance costs (predominantly Ind AS 116 interest on lease liabilities tied to the expanding store network) rose to ₹250.0 Cr from ₹213.3 Cr a year ago, and depreciation (mostly right-of-use asset depreciation) also stepped up — together these absorbed almost all of the operating gains from the 21% revenue growth.

₹
579.54618.7657.85697736.16621.4507-2408-1709-0810-0110-27Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹621.45, down 5.3% over the past month of trading.

₹ Cr
023.8847.7771.6542.34Q1 FY26rev ₹1,543 Cr55.5Q2 FY26rev ₹1,679 Cr57.79Q3 FY26rev ₹1,806 Cr63.97Q4 FY26rev ₹1,864 Cr33.17Q1 FY27rev ₹1,880 Cr56.07Q2 FY27rev ₹2,037 Cr
Quarterly consolidated PAT, ₹ Crore
What management guided (1 FY-2027 call)
FY27: 800 net store additions (146 added Q1). Gross margins to recover via private label growth (+0.3–0.5% quarterly). FY27 operating EBITDA target remains ₹400 Cr (no revision).

— This quarter: met

No management press release or MD&A commentary accompanied this filing beyond the standard regulatory notes, so management's own framing of the quarter can't be cross-checked here. Against the prior concall's guidance, gross-margin recovery is tracking (met), but the FY27 target of 800 net store additions (146 added in Q1) and the ₹400 Cr operating EBITDA target are not independently verifiable from this Ind AS 34 statement — no store count or pre-lease EBITDA figure is disclosed this quarter. Street commentary ahead of the print (Univest's Q2 preview) framed the quarter as a test of whether margins stabilize back toward the 8-9% band seen through most of the last five quarters after Q1's dip to ~7.1%; no firm consensus PAT/revenue figure could be sourced, so vsStreet is marked unknown rather than guessed. Standalone (parent-only) PAT, by contrast, rose a sharp 68.3% YoY to ₹26.3 Cr (₹15.6 Cr) on revenue up 36.2% to ₹280.1 Cr — a basis divergence worth flagging explicitly, since the standalone entity carries a far smaller lease/store base than the full consolidated retail network, so it doesn't absorb the same Ind AS 116 cost drag.

  • W1

    Gross margin pace: whether the +58 bps QoQ private-label-led gain continues to close the ~108 bps YoY gap toward the guided +0.3-0.5pp/quarter recovery

  • W2

    Store-count disclosure: progress toward the FY27 target of 800 net store additions (146 added in Q1) — not disclosed in this filing, watch the next investor update/concall

  • W3

    Finance-cost trajectory: consolidated finance costs at ₹250.0 Cr this quarter (+17.2% YoY) against the unchanged FY27 operating EBITDA target of ₹400 Cr

Both statements legible, reviewed (not audited) by B S R and Co on 27 Oct 2026; totalIncome and PAT checks match exactly on both bases. No exceptional items disclosed. Consolidated PAT of ₹56.069 Cr is group net profit (III-IV); ₹56.075 Cr attributable to owners after a ₹0.06 Cr NCI loss — immaterial difference.

Informational and educational content only. Not investment advice.